The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | An overview of clinical trials investigating BTK inhibitors and degraders in MCL
Michael Wang, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, gives an overview of promising clinical trials exploring BTK inhibitors in mantle cell lymphoma (MCL). He mentions the approval of several BTK inhibitors, and ongoing trials investigating BTK degraders. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So in the past, the promising clinical trials was the ibrutinib study, published in New England Journal of Medicine in November 2013. And then we have the acalabrutinib clinical trial, single agent, led to FDA approval. Then we have the BGB, zanubrutinib approval...
So in the past, the promising clinical trials was the ibrutinib study, published in New England Journal of Medicine in November 2013. And then we have the acalabrutinib clinical trial, single agent, led to FDA approval. Then we have the BGB, zanubrutinib approval. And then we have pirotobrutinib approval. And now we are studying BTK inhibitors. actually, BTK degraders. So the promising trials are, there are several trials on studying BTK degraders, and one of them is, so one of them is sponsored by BeiGene company, and this is an international trial, it’s enrolled CLL and mantle cell lymphoma and other malignancies. And Dr. John Seymour from Peter MacCann Center, Australia, presented the data last ASH and shows very good overall response rates and tolerability. So we are enrolling at the MD Anderson with mantle cell lymphoma and on the same study. And I think it’s a promising study.
Read more...
